Category - Markets

Markets

BTIG starts Beyond Air at buy; PT $15

BTIG initiated coverage of Beyond Air (NASDAQ:XAIR) with a “buy” rating and $15 price target. The stock closed at $5.73 on June 14. Beyond Air is a medical device company that has developed a technology to turn room air...

June 15, 2023

Markets

AGP starts UpHealth at buy; PT $4.30

Alliance Global Partners initiated coverage of UpHealth (NYSE:UPH) with a “buy” rating and price target of $4.30. The stock closed at $1.45 on June 8. UpHealth operates as a digital health services company in the...

June 9, 2023

Markets

Research Capital ups Profound Medical to speculative buy; PT to $17.25

Research Capital upgraded Profound Medical (NASDAQ:PROF; TSX:PRN) to “speculative buy” from “hold” and raised its price target to $17.25 from $10.90, after the AMA approved three new Category 1 CPT codes for prostate...

June 5, 2023

Markets

Research Capital likes Theralase data update; sees FDA breakthrough filing soon

Research Capital remains bullish on the ability of Theralase Technologies’ (TSXV:TLT; OTCQB:TLTFF) Ruvidar to treat BCG-unresponsive non-muscle invasive bladder cancer (NMIBC), given the “strong data that has...

May 31, 2023

Markets

SVB ups Elevation Oncology to OP; PT to $8 on clinical update

SVB Securities upgraded Elevation Oncology (NASDAQ:ELEV) to “outperform” from “market perform” and raised its price target to $8 from $5, following the abstract release for EO-3021 (Claudin 18.2) ahead of ASCO. “This is...

May 30, 2023

Markets

Stifel ups eFFECTOR to buy; PT to $7 on revaluating breast cancer

Stifel upgraded eFFECTOR Therapeutics (NASDAQ:EFTR) to “buy” from “hold” and raised its price target to $7 from $1.30, saying the “zotatifin combo is emerging as an active and underappreciated asset in breast cancer.”...

May 26, 2023

Markets

Analysts give high marks to Hepion’s ATTITUDE NASH trial results

Analysts for Cantor Fitzgerald and Brookline Capital Markets gave high marks to Hepion Pharmaceuticals’ (NASDAQ:HEPA) Phase 2a ATTITUDE NASH trial results, which met its primary and secondary endpoints as well as showed...

May 22, 2023

Markets

Cantor starts Acumen Pharma at OW; PT $13

Cantor Fitzgerald initiated coverage of Acumen Pharmaceuticals (NASDAQ:ABOS) with an “overweight” rating and 12-month price target of $13. The stock closed at $5.45 on May 17. Acumen is a neuro-Innovator leveraging its...

May 19, 2023

Markets

BTIG starts Coya Therapeutics at buy; PT $15

BTIG launched coverage of Coya Therapeutics (NASDAQ:COYA) with a “buy” rating and a $15 price target. The stock closed at $5.76 on May 17. Analyst Thomas Shrader, Ph.D., writes that his price target is based on “our...

May 18, 2023

Markets

Cantor and Brookline change Hepion PTs to $28 and $74 post-split

Cantor Fitzgerald raised its price target for Hepion Pharmaceuticals (NASDAQ:HEPA) to $28 after a one-for-20 reverse stock split on May 10, and maintained an “overweight” rating. The stock closed at $6.81 on Friday. “We...

May 15, 2023

Category - Markets

Subscribe